Get started
Author

Oğuzhan Selvi

ORCID: 0000-0003-4465-1107
Observed ORCID: 0000-0003-4465-1107
OpenAlex ID: A5137549271
Targeting Ceramide Metabolism to Overcome Osimertinib Resistance in EGFR-mutant Non-Small Cell Lung Cancer: An In Vitro, Network Pharmacology, and In Silico Study
2026 · Oğuzhan Selvi, Canan Vejselova Sezer, et al. · Anti-Cancer Agents in Medicinal Chemistry · 1
Therapeutic Effects of Ceranib-2 and Irinotecan Combination on Colon Cancer
2026 · Oğuzhan Selvi, Canan Vejselova Sezer, et al. · Current Issues in Molecular Biology
MCV–Neutropenia Risk Score and Overall Survival in HR+/HER2− Advanced Breast Cancer: A Multicenter Retrospective Landmark Analysis
2026 · Fatih Atalah, Aydın Acarbay, et al. · Breast Cancer Targets and Therapy
PDF
Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature
2026 · Cevat İlteriş Kıkılı, Murat Araz, et al. · Clinical Genitourinary Cancer
Works count: 4
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type